Clinical trials
NPC clinical trials
Below are recruiting npc clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT07013461Recruiting
Nasopharyngeal cancer staging study
This study looks at how well the current cancer staging system works for nasopharyngeal cancer. If you have been diagnosed with this type of cancer between October 2025 and September 2026, you may be able to join.
Shenzhen, GuangdongAges 18 years+ - NCT07376603Recruiting
Radiation therapy alone for early-stage nasopharyngeal cancer
This trial tests whether intense radiation therapy (IMRT) alone is effective for people with stage IB nasopharyngeal carcinoma (a type of head and neck cancer) that has not spread to lower lymph nodes or formed large, matted nodes. If you qualify, you would receive targeted radiation without chemotherapy.
Fuzhou, FujianAges 18–70 - NCT06912698RecruitingPhase 3
Lower vs. standard radiation for early nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
Guangzhou, GuangdongAges 18–70 - NCT07082725RecruitingPhase 3
Study of oral nizubaglustat for Niemann-Pick type C
This study tests an oral medication called nizubaglustat for people with Niemann-Pick type C disease who cannot take or are not satisfied with the current treatment miglustat. It aims to see if the drug can help with symptoms like coordination and movement problems.
Oakland, CaliforniaAges 4 years+ - NCT07706985RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT03919552RecruitingPhase 3
Chemoradiation with two cisplatin or carboplatin plans for nasopharyngeal cancer
This Phase 3 trial compares two chemotherapy-and-radiation combinations (cisplatin-based vs carboplatin-based) for locally advanced nasopharyngeal cancer that has not spread to distant organs. It may help researchers find which plan works best while balancing safety and effectiveness.
Guangzhou, GuangdongAges 18–64 - NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65 - NCT04830267RecruitingPhase 2
Camrelizumab plus focused radiation for recurrent metastatic nasopharyngeal cancer
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05340491RecruitingPhase 3
Radiation plus immunotherapy for repeat nasopharyngeal cancer
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
Guangzhou, GuangdongAges 18–70 - NCT05514275RecruitingPhase 2
Radiation plus endostatin and capecitabine for nasopharyngeal cancer
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
Hangzhou, ZhejiangAges 18–65 - NCT05628922RecruitingPhase 2
Blood EBV DNA–guided therapy for advanced nasopharyngeal cancer
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT06059261RecruitingPhase 2
Envafolimab plus chemoradiation and endostatin for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (envafolimab) with standard chemoradiation and a drug that blocks blood vessel growth (endostatin) for people with advanced nasopharyngeal cancer that hasn't been treated before. The goal is to see if this combination works better than the usual treatment.
Chongqing, Chongqing MunicipalityAges 18–65 - NCT06177301RecruitingPhase 3
Comparing two drug combos for recurrent nasopharyngeal cancer
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06182657Recruiting
Nasopharyngeal cancer response to induction chemotherapy
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Nanchang, JiangxiAges 18 years+ - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06228079RecruitingPhase 3
Chemo-immunotherapy after surgery for early reoccurring nasopharyngeal cancer
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06235203RecruitingPhase 3
Comparing treatment timing in recurrent nasopharyngeal cancer
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06241599RecruitingPhase 2/Phase 3
AK104 with chemo for advanced nasopharyngeal cancer
This study tests if adding a new immunotherapy drug (called AK104) to standard chemotherapy can help people whose nasopharyngeal cancer has come back or spread after previous treatment. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT06241612RecruitingPhase 3
Personalized neck radiation for nasopharyngeal cancer
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06389201Recruiting
Hydroxychloroquine before radiation and chemo for NPC
This trial tests whether taking hydroxychloroquine (HCQ) before standard radiation and chemo can help treat advanced nasopharyngeal cancer. It is for patients who have not yet started any cancer therapy.
Nantong, JiangsuAges 20–70
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for npc?
- Yes. Clin2 currently lists 76 recruiting npc studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a npc trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a npc trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.